ClearPoint Neuro, Inc. (NASDAQ:CLPT) Short Interest Down 22.1% in January

ClearPoint Neuro, Inc. (NASDAQ:CLPT - Get Free Report) was the recipient of a significant decrease in short interest in January. As of January 31st, there was short interest totalling 653,400 shares, a decrease of 22.1% from the January 15th total of 838,600 shares. Based on an average daily volume of 235,700 shares, the short-interest ratio is presently 2.8 days.

Institutional Investors Weigh In On ClearPoint Neuro

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in CLPT. R Squared Ltd acquired a new stake in ClearPoint Neuro during the 4th quarter valued at approximately $32,000. AlphaQuest LLC acquired a new position in ClearPoint Neuro during the fourth quarter worth $80,000. Barclays PLC increased its stake in shares of ClearPoint Neuro by 24.3% during the third quarter. Barclays PLC now owns 5,674 shares of the company's stock worth $64,000 after purchasing an additional 1,109 shares in the last quarter. Tower Research Capital LLC TRC acquired a new position in shares of ClearPoint Neuro during the fourth quarter valued at approximately $93,000. Finally, State of Wyoming acquired a new stake in ClearPoint Neuro during the 4th quarter worth $145,000. 30.08% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Several analysts recently issued reports on the company. Lake Street Capital increased their target price on ClearPoint Neuro from $17.00 to $30.00 and gave the stock a "buy" rating in a research report on Tuesday, January 21st. B. Riley increased their price target on ClearPoint Neuro from $15.00 to $20.00 and gave the stock a "buy" rating in a report on Tuesday, January 28th.

ClearPoint Neuro Price Performance

Shares of CLPT stock traded down $0.72 during mid-day trading on Wednesday, hitting $17.91. 311,846 shares of the stock traded hands, compared to its average volume of 202,126. The stock's fifty day moving average is $16.56 and its two-hundred day moving average is $13.48. ClearPoint Neuro has a 52-week low of $5.11 and a 52-week high of $19.22. The stock has a market cap of $493.96 million, a P/E ratio of -25.96 and a beta of 1.03.

ClearPoint Neuro Company Profile

ClearPoint Neuro, Inc operates as a medical device company primarily in the United States. It develops and commercializes platforms for performing minimally invasive surgical procedures in the brain under magnetic resonance imaging guided interventions. The company offers ClearPoint system, an integrated system for the insertion of deep brain stimulation electrodes, biopsy needles, and laser catheters, as well as the infusion of pharmaceuticals into the brain.